Suppressive effect of saprogrelate hydrochloride on Raynaud's phenomenon and respiratory failure in patients with systemic sclerosis
| Autor: | Shingo Okamoto, Keiji Takasaki, N. Ohnuma, A Nakamoto, Shiro Kato, H Kumamoto, Noboru Kaneko, Izumi Kishiro |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Pulmonary Fibrosis Thrombomodulin Blood Pressure Pulmonary Artery Platelet Factor 4 Gastroenterology Pulmonary function testing Leukocyte Count FEV1/FVC ratio DLCO Oral administration White blood cell Internal medicine medicine Humans Aged Fibrinopeptide A Scleroderma Systemic business.industry Raynaud Disease Middle Aged beta-Thromboglobulin C-Reactive Protein medicine.anatomical_structure Blood pressure Respiratory failure Anesthesia Arterial blood Female Serotonin Antagonists Pulmonary Ventilation Respiratory Insufficiency business |
| Zdroj: | Respirology. 5:27-32 |
| ISSN: | 1440-1843 1323-7799 |
| Popis: | Objective: In seven patients with systemic sclerosis (SS), we evaluated the clinical effectiveness of oral administration of saprogrelate hydrochloride (SH: 300 mg/day) for 2 months on Raynaud’s phenomenon (RP) and respiratory failure estimated by Hugh-Jones classification. Methodology: We evaluated laboratory data (arterial blood gas (pH, PaO2 and PaCO2), pulmonary function tests (%VC, FEV1/FVC and %DLco), mean pulmonary arterial pressure (mPAP), white blood cell count, C-reactive protein and the plasma levels of fibrinopeptide A (FPA), β-thrombogloblin (β-TG), platelet factor 4 (PF4) and thrombomodulin (TM)) before and after SH administration. Results: The frequency and duration of RP, as well as the coldness, numbness and pain of RP were significantly decreased after SH administration (P < 0.05, P < 0.01 and P < 0.001). Respiratory failure estimated by Hugh-Jones classification was also significantly decreased after SH administration (P < 0.05), and the %DLco was significantly increased (P < 0.01). The mPAP decreased significantly after SH administration (P < 0.05). Plasma FPA, β-TG and PF4 significantly decreased after administration (P < 0.05 and P < 0.01). Conclusions: SH therapy could prevent RP and respiratory failure in patients with SS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text